Clinical Trials Directory

Trials / Active Not Recruiting

Active Not RecruitingNCT01843413

Stereotactic Radiosurgery in Treating Patients With Large Brain Metastases

Dose Escalation for Larger Brain Metastases: Phase I/II Study

Status
Active Not Recruiting
Phase
Phase 1
Study type
Interventional
Enrollment
33 (actual)
Sponsor
Case Comprehensive Cancer Center · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This phase I/II trial studies the side effects and the best dose of stereotactic radiosurgery and to see how well it works in treating patients with large brain metastases. Radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue.

Detailed description

PRIMARY OBJECTIVES: I. To determine the incidence of acute and long-term toxicities with increasing dose of stereotactic radiosurgery (SRS). (Phase I) II. To determine if local control may be improved with increasing doses of SRS. (Phase II) SECONDARY OBJECTIVES: I. To determine the risk of acute and long-term toxicity with increasing dose of SRS. (Phase II) II. To determine if there is increased neurocognitive toxicity with increased dose of SRS. III. To determine the rate of radiation necrosis/steroid dependency. IV. To determine if quality of life is affected more by tumor recurrence versus radiation necrosis. This includes assessment of progression free survival, overall survival, local failure, and number of patients who receive bevacizumab, laser interstitial thermal therapy, or surgery for presumed radiation necrosis. OUTLINE: This is a phase I dose-escalation study followed by a phase II study. Patients undergo SRS guided by computer tomography (CT) and magnetic resonance imaging (MRI). After completion of treatment, patients are followed up at 1-2, 3, 6, 9, and 12 months, every 3 months for 2 years, and then every 4 months thereafter.

Conditions

Interventions

TypeNameDescription
RADIATIONstereotactic radiosurgeryUndergo SRS
PROCEDUREquality-of-life assessmentAncillary studies
PROCEDUREcognitive assessmentAncillary studies

Timeline

Start date
2013-07-02
Primary completion
2025-08-01
Completion
2025-08-01
First posted
2013-04-30
Last updated
2025-07-20

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT01843413. Inclusion in this directory is not an endorsement.